Therapeutic destruction of insulin receptor substrates for cancer treatment.
about
Pathways and therapeutic targets in melanomaThe struggle by Caenorhabditis elegans to maintain proteostasis during aging and diseaseThe Novel Functions of High-Molecular-Mass Complexes Containing Insulin Receptor Substrates in Mediation and Modulation of Insulin-Like Activities: Emerging Concept of Diverse Functions by IRS-Associated ProteinsCDK4 is an essential insulin effector in adipocytesLack of association between insulin receptor substrate2 rs1805097 polymorphism and the risk of colorectal and breast cancer: a meta-analysis.IGF-I regulates redox status in breast cancer cells by activating the amino acid transport molecule xC-.IRS-2 rs1805097 polymorphism is associated with the decreased risk of colorectal cancerMiR-570 inhibits cell proliferation and glucose metabolism by targeting IRS1 and IRS2 in human chronic myelogenous leukemia.Role of insulin receptor substrates in the progression of hepatocellular carcinoma.PHIPing out: a genetic basis for tumor ulceration.Phosphoproteomic Analysis of Cell-Based Resistance to BRAF Inhibitor Therapy in Melanoma.Alcohol Consumption Modulates Host Defense in Rhesus Macaques by Altering Gene Expression in Circulating Leukocytes.Tissue and serum IGFBP7 protein as biomarker in high-grade soft tissue sarcomaTargeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling.IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms.CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo EfficacymicroRNA-7-5p inhibits melanoma cell proliferation and metastasis by suppressing RelA/NF-κB.Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation.Worming our way to novel drug discovery with the Caenorhabditis elegans proteostasis network, stress response and insulin-signaling pathways.Minireview: Were the IGF Signaling Inhibitors All Bad?Suppression of B-Raf(V600E) cancers by MAPK hyper-activationPTEN regulates IGF-1R-mediated therapy resistance in melanoma.A novel inhibitor of the insulin/IGF signaling pathway protects from age-onset, neurodegeneration-linked proteotoxicity.Mixed Mesonephric Adenocarcinoma and High-grade Neuroendocrine Carcinoma of the Uterine Cervix: Case Description of a Previously Unreported Entity With Insights Into Its Molecular Pathogenesis.Preclinical Effectiveness of Selective Inhibitor of IRS-1/2 NT157 in Osteosarcoma Cell Lines.Bis-anthracycline WP760 abrogates melanoma cell growth by transcription inhibition, p53 activation and IGF1R downregulation.Trial Watch: Peptide vaccines in cancer therapy.Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.LPIN1 promotes epithelial cell transformation and mammary tumourigenesis via enhancing insulin receptor substrate 1 stability.Revisiting the IGF-1R as a breast cancer target.Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling.An exon variant in insulin receptor gene is associated with susceptibility to colorectal cancer in women.Postprandial increase in serum CA125 as a surrogate biomarker for early diagnosis of ovarian cancer.miR-130a and miR-145 reprogram Gr-1+CD11b+ myeloid cells and inhibit tumor metastasis through improved host immunity.New susceptibility loci for cutaneous melanoma risk and progression revealed using a porcine model.Association of IRS2 overexpression with disease progression in intrahepatic cholangiocarcinoma
P2860
Q26865736-01CEC2F2-564B-4BD3-BB98-DBE6C2C2C773Q28069294-EB2B34D3-7853-4372-8459-AF9EBA5F36B1Q28088661-9626BA2D-6705-45CD-BA0A-65B8D546489FQ28585816-7E8FFEB5-5E99-491A-B5E7-FE4FB341452EQ31150038-0315C88D-CBAE-40C7-A77E-49DE525BAB7DQ33551399-DA9B15F4-3B2B-442D-A22F-AA0D9DF9C619Q33648770-5E62C64A-9C09-459E-8135-1C49D01098D5Q33819570-FE709D76-09D9-49FA-9F75-CAEB0D4A5A88Q33905578-AFDAFCAF-624F-4087-BFFA-28E100364D2BQ35546486-49CC7643-3AA4-43B4-9B72-AA3C00956395Q35609071-700194D6-DDD6-4593-9540-E100F7250DDAQ36387183-F700F153-9E4B-4D40-A87F-27496673A2F7Q36420180-BFEE81C7-C2F8-4B4B-A77D-857E7D75F7D0Q36685345-10603800-5847-44A6-8614-E67EC2B9A1EEQ36916389-16848068-2CDA-4C7C-99FA-E1E84E9C535BQ36978557-EF3D4354-9640-425E-B12B-DCD1FD6B2CCDQ37362485-6DFBE2B2-4E1D-4637-88C8-502CB98395D0Q37660331-84820539-F539-4A17-800C-05DEB6FD6858Q38226757-C1745DDF-04D8-46AD-94DD-142A69363E53Q38586367-62E03346-AA3F-4DB9-A773-77CDE2D44015Q38787620-813B1AE7-0880-43C2-900D-85FAF77713A4Q38859960-1C0A7959-7C06-41E2-B9BE-DB31D3EB9E2EQ39059383-B770E8BF-DD0F-491A-862A-38BE1937D3B4Q39483070-048DFE5A-60FE-4832-BBD7-E7EDDDD84164Q40606069-1C4F1D76-C20A-4AEC-A479-253BC22E5DB4Q42363777-33231940-3141-4420-A8C6-38C3F153BD30Q42734544-AA217119-C406-4D16-8B11-108FD1BE3BF5Q46300809-6AE1BB18-3A67-4F1E-9EE6-4BE73D5ED304Q51405942-222B1FF6-DED1-4EB3-A269-91A5A0081245Q52686152-A822BC39-3597-4611-9EE4-A6866F746D04Q53835262-45080818-1EC9-41B0-8723-BA0160599EDFQ54298814-5EC38C11-C710-4CD9-951C-F13A9FA98BB0Q54966156-EEE2809A-B52A-4A94-BF62-685FEF09B725Q55434830-BE5B5F70-148F-41C0-A414-0A926D2E9D4AQ55513422-01684593-48DB-4372-AA5E-5D514036024BQ58794872-6539A485-BFA8-4D92-962B-B260F0602CE0
P2860
Therapeutic destruction of insulin receptor substrates for cancer treatment.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Therapeutic destruction of insulin receptor substrates for cancer treatment.
@ast
Therapeutic destruction of insulin receptor substrates for cancer treatment.
@en
type
label
Therapeutic destruction of insulin receptor substrates for cancer treatment.
@ast
Therapeutic destruction of insulin receptor substrates for cancer treatment.
@en
prefLabel
Therapeutic destruction of insulin receptor substrates for cancer treatment.
@ast
Therapeutic destruction of insulin receptor substrates for cancer treatment.
@en
P2093
P2860
P1433
P1476
Therapeutic destruction of insulin receptor substrates for cancer treatment.
@en
P2093
Alexander Levitzki
Alexei Shir
Efrat Flashner-Abramson
Hadas Reuveni
Kirill Makedonski
Lilach Steiner
Menashe Bar-Eli
Renduo Song
P2860
P304
P356
10.1158/0008-5472.CAN-12-3385
P407
P577
2013-05-07T00:00:00Z